Procyrion Stock

www.procyrion.comHealthcare / Medical DevicesFounded: 2005

Procyrion is aiding the Aortix™ device, designed for percutaneous mechanical circulatory support to benefit heart and kidney functions. By pumping blood from the aortic arch to the lower aorta, it aims to reduce heart workload and improve cardiac efficiency while also enhancing renal perfusion. This could potentially aid in conditions like diuretic-resistant heart failure. Preclinical studies suggest its application in acute heart failure, renal support during cardiac procedures, myocardial infarct size reduction, and chronic heart failure management.

Register To Buy and Sell Shares

For more details on financing and valuation for Procyrion, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access Procyrion’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Procyrion.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Register

Animation displayed is not current and securities are shown for illustrative purposes only.

Procyrion investors also invested in these private companies

Bluebird Ventures
Fannin Innovation Studio
Texas Ventures
Scientific Health Development
Texas Emerging Technology Fund

Team

Management Team

Reynolds Delgado MD
Founder & Chief Medical Officer
Eric Fain MD
Chief Executive Officer & President
Jason Heuring Ph.D
Chief Scientific Officer & Chief Operating Officer
Av Edidin Ph.D
Senior Vice President, Development & Manufacturing
Elisabeth Neely
Senior Vice President of Clinical and Regulatory Affairs

Board Members

Carter Meyer JD
Scientific Health Development
Leo Linbeck III
Fannin Innovation Studio

Frequently Asked Questions About Procyrion’s Stock

plusminus
Can you buy Procyrion’s stock?
Procyrion is not publicly traded on NYSE or NASDAQ in the U.S. To buy Procyrion’s stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
plusminus
Can you sell Procyrion’s stock?
Yes, you can sell stock of a private company like Procyrion. Forge can help you sell your Procyrion stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
plusminus
What is Procyrion’s stock price?
Procyrion is a privately held company and therefore does not have a public stock price. However, you may access Procyrion’s private market stock price with Forge Data.
plusminus
What is Procyrion’s stock ticker symbol?
Procyrion does not have an official ticker symbol because this company is not currently publicly traded.
plusminus
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

PROCYRION CLOSES $57.7 MILLION IN SERIES E FINANCING
Procyrion, Inc., specializing in medical devices for cardiac and renal impairment, has successfully raised $57.7 million in Series E funding, led by Fannin Partners. This will fuel the DRAIN-HF trial for their Aortix device in treating acute decompensated heart failure (ADHF) patients, as well as support manufacturability improvements and commercialization efforts. Aortix aims to offer a groundbreaking solution for cardiorenal syndrome (CRS) patients, promising improved outcomes for this high-need group.
Procyrion Closes $57.7 Million in Series E Financing
Procyrion™, Inc., a medical device company dedicated to improving outcomes for patients with cardiac and renal impairment, announced today the completion of a $57.7 million Series E funding round, including the conversion of $10.0 million of interim financing. These funds will be used to support the ongoing DRAIN-HF pivotal IDE trial evaluating the Aortix™ percutaneous mechanical circulatory support (pMCS) device in patients with acute decompensated heart failure (ADHF) who remain congested despite standard medical therapy (cardiorenal syndrome or CRS).
Updated on: Jun 12, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.